与选择性血清素再吸收抑制剂 (SSRI) 相关的心脏膜不称职:从全球安全报告中分析不成比例和风险因素
Adrian Chin Yan Chan1, Yue Han2
1Pharmacology, Bayer Pharmaceuticals, Beijing, CHN.
Cureus
|February 16, 2026
概括
选择性血清素再吸收抑制剂 (SSRI) 可能与心脏膜问题有关,特别是帕洛和塞特拉林. 以前存在的心脏病和某些其他药物增加了这种风险,因此需要进一步调查SSRI的安全性.
科学领域:
- 药物监督 药物监督 药物监督
- 心脏病学 心脏病学
- 心理药理学 心理药理学
背景情况:
- 选择性血清素再吸收抑制剂 (SSRI) 是广泛处方的抗抑郁药.
- 新出现的证据表明,SSRI和膜心脏病 (VHD) 之间存在潜在的联系.
- 这种关联可能涉及血清素载体 (SERT) 抑制和5-HT2B受体激活.
研究的目的:
- 调查与SSRI使用相关的心脏膜不称职的潜在安全信号.
- 分析来自世界卫生组织的全球药监数据库 (VigiBase) 的数据.
- 为了确定SSRI相关的膜病变的风险因素.
主要方法:
- 使用VigiBase来检查六种SSRI的安全信号:塞特拉林,帕洛克塞丁,克塞丁,弗卢瓦克萨明,西塔洛普拉姆和埃斯卡托普拉姆.
- 使用信息组件 (IC) 统计数据进行了不成比例分析.
- 采用后勤回归分析来确定门病变的危险因素.
主要成果:
- 帕洛克塞丁和塞特拉林对心脏膜不称职的显著安全信号被确定,特别是对肺和三管.
- 后勤回归显示,心脏并发症和同时使用影响血清通路的药物是独立的风险因素.
- 在对共变量进行调整后,这些关联仍然显著,证实了它们的稳定性.
结论:
- 全球药监数据表明帕罗丁,塞特拉林,素和心脏膜不称职之间存在潜在的关联.
- 帕洛西丁和塞特拉林表现出最强烈的安全信号.
- 进一步的研究,包括前性研究和机制性调查,对于证实这些发现和了解潜在机制至关重要.
相关概念视频
01:28Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
1.7K
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
1.7K
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
1.1K
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
1.1K
01:23Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
718
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
718
01:23Antidepressant Drugs: MAOIs and Other Agents
964
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
964
01:25Antidepressant Drugs: Overview
1.6K
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
1.6K
01:24Drug Toxicity: Risk factors
18
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
18